Novo Nordisk A/S ADR (NVO) News
Filter NVO News Items
NVO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NVO News Highlights
- For NVO, its 30 day story count is now at 23.
- Over the past 21 days, NVO's stories per day has been in a clear uptrend, growing by about 0.96 per 18 hours.
- DRUG, TOP and ABBV are the most mentioned tickers in articles about NVO.
Latest NVO News From Around the Web
Below are the latest news stories about NOVO NORDISK A S that investors may wish to consider to help them evaluate NVO as an investment opportunity.
Pfizer stock rises on positive results from weight loss drug studyYahoo Finance's Rachelle Akuffo details a rise in Pfizer stock after the company announced positive results from the study of a new weight loss drug. |
Novo Nordisk's Oral Weight-Loss Drug Shows Significant BenefitNovo Nordisk A/S (NYSE: NVO) announced headline results from OASIS 1 Phase 3a trial in the global OASIS program. OASIS 1 is a 68-week, efficacy, and safety trial comparing once-daily oral semaglutide 50 mg for weight management to a placebo in 667 adults with obesity or overweight with one or more comorbidities. Semaglutide is a peptide sold by Novo Nordisk under Ozempic, Rybelsus, and Wegovy for the long-term treatment of type 2 diabetes or obesity. The trial achieved its primary endpoint by de |
Pfizer Stock Jumps After Diabetes Drug Tops Ozempic In Weight LossAn oral drug from Pfizer led to faster weight loss than weekly injections of Novo Nordisk's diabetes drug Ozempic. Pfizer stock jumped. |
AbbVie (ABBV) Gets FDA Nod for Lymphoma Drug EpcoritamabThe FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large B-cell lymphoma, a form of NHL. Epkinly is AbbVie's third blood cancer drug. |
UPDATE 3-Pfizer's diabetes drug results in similar weight loss levels as Novo's OzempicShares of Pfizer rose about 4.5% following the news, which comes at a time of increased investor interest in the weight-loss treatment market, which is estimated to reach $100 billion by the end of the decade. Pfizer's danuglipron, when given twice a day, lowered blood sugar in patients at all doses and reduced body weight at the highest dose after 16 weeks compared to placebo, according to mid-stage data published last year by the U.S. drugmaker. |
UPDATE 4-Novo Nordisk, Pfizer weight-loss pills work as well as shotsNovo Nordisk and Pfizer Inc separately released data on Monday showing that pills from the same class as Novo's increasingly popular weight loss drugs such as Wegovy are about as effective as those injected medicines, giving shares of both companies a boost. Novo Nordisk said data from a late-stage trial showed an oral version of its drug semaglutide helped overweight or obese adults lose weight comparable to what is seen with injected Wegovy, which has the same active ingredient. |
Novo Nordisk A/S: Oral semaglutide 50 mg achieved 15.1% weight loss (17.4% if all people adhered to treatment) in adults with obesity or overweight in the OASIS 1 trialBagsværd, Denmark, 22 May 2023 – Novo Nordisk today announced headline results from OASIS 1, a phase 3a trial in the global OASIS programme. OASIS 1 is a 68-week, efficacy and safety trial comparing once-daily oral semaglutide 50 mg for weight management to placebo in 667 adults with obesity or overweight with one or more comorbidities. Both treatment arms were in conjunction with lifestyle intervention. The trial achieved its primary endpoint by demonstrating a statistically significant and sup |
Novo Nordisk A/S - share repurchase programmeBagsværd, Denmark, 22 May 2023 – On 9 May 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. Under the programme-initiate |
Take the Zacks Approach to Beat the Market: Shopify, Brambles, McDonald's in FocusOur time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months. |
Obesity drug brings heart health benefit alongside weight loss- studyTaking Novo Nordisk’s new obesity drug may help reduce the risk of heart disease as well as boosting weight loss, according to new research from the United States. After a year of taking semaglutide, marketed as Wegovy, patients’ risk of suffering from conditions like a heart attack or a stroke over the next ten years dropped to 6.3% from 7.6% when measured by a commonly used calculator, researchers at the Mayo Clinic found. The results, which were presented this week at the European Congress on Obesity in Dublin, are among the first indication that the weight loss induced by the new GLP-1 agonist drugs like Wegovy also brings heart health benefits – something scientists expected, but do not yet have much comprehensive data to prove. |